Evidence map›Paper›PMID 40001177›Full record

ArticleJournal of cheminformatics2025

DrugDiff: small molecule diffusion model with flexible guidance towards molecular properties.

Marie Oestreich, Erinc Merdivan, Michael Lee, Joachim L Schultze, Marie Piraud, Matthias Becker

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. SynthesizabilityChemical science · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marie OestreichModular High-Performance Computing and Artificial Intelligence, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Marie.Oestreich@dzne.de.
Erinc MerdivanHelmholtz AI, Helmholtz Munich, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Michael LeeModular High-Performance Computing and Artificial Intelligence, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Joachim L SchultzeSystems Medicine, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Marie PiraudHelmholtz AI, Helmholtz Munich, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Matthias BeckerModular High-Performance Computing and Artificial Intelligence, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Matthias.Becker@dzne.de.

Funding

Bundesministerium für Bildung und Forschung 16KISA030Helmholtz Artificial Intelligence Cooperation Unit ZT-I-PF5-23
6 · The paper itself

Abstract

With the cost/yield-ratio of drug development becoming increasingly unfavourable, recent work has explored machine learning to accelerate early stages of the development process. Given the current success of deep generative models across domains, we here investigated their application to the property-based proposal of new small molecules for drug development. Specifically, we trained a latent diffusion model-DrugDiff-paired with predictor guidance to generate novel compounds with a variety of desired molecular properties. The architecture was designed to be highly flexible and easily adaptable to future scenarios. Our experiments showed successful generation of unique, diverse and novel small molecules with targeted properties. The code is available at https://github.com/MarieOestreich/DrugDiff . SCIENTIFIC CONTRIBUTION: This work expands the use of generative modelling in the field of drug development from previously introduced models for proteins and RNA to the here presented application to small molecules. With small molecules making up the majority of drugs, but simultaneously being difficult to model due to their elaborate chemical rules, this work tackles a new level of difficulty in comparison to sequence-based molecule generation as is the case for proteins and RNA. Additionally, the demonstrated framework is highly flexible, allowing easy addition or removal of considered molecular properties without the need to retrain the model, making it highly adaptable to diverse research settings and it shows compelling performance for a wide variety of targeted molecular properties.

Indexed as

Drug developmentGenerative modellingLatent diffusionTargeted generation

Identifiers

PMID40001177
PMCPMC11854002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.